ArticleOpen forum infectious diseases2018
Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Rare genetic variant risks in patients with sepsis-associated acute respiratory distress syndrome.Respiratory research · 2026Article
- Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis.Clinical genetics · 2025Article
- Breaking boundaries or a small piece of the puzzle: can CFTR modulators transform bronchiectasis care?ERJ open research · 2025Article
- The Increased Risk for Postinfluenza Pneumonia Among Cystic Fibrosis Carriers-A Population-Based Study.Open forum infectious diseases · 2025Article
- Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk.Pediatric pulmonology · 2025Article
- Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes.JAMA internal medicine · 2025Article
- The Spectrum and Carrier Frequencies of Common Pathogenic Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations in Men from the General Population: The Role of Ethnicity.International journal of molecular sciences · 2025Article
- Novel Co-Occurrence of Trisomy 21 and Heterozygous CFTR Mutation.Respirology case reports · 2025Article
- CFTR as a therapeutic target for severe lung infection.American journal of physiology. Lung cellular and molecular physiology · 2025Review
- Predicting valuable missense variants with AlphaMissense in a multiple pulmonary infection patient.Clinical case reports · 2024Article
- Cystic Fibrosis Carrier States Are Associated With More Severe Cases of Bronchiectasis.Open forum infectious diseases · 2024Article
- Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis.The Journal of clinical investigation · 2022Article
- The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries.The Journal of infection · 2022Article
- CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.JCI insight · 2022Article
- Clinical Phenotypes of Cystic Fibrosis Carriers.Annual review of medicine · 2022Review
- Severe COVID-19 in Hospitalized Carriers of SingleJournal of personalized medicine · 2021Article
- Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVID-19?Journal of cellular and molecular medicine · 2020Article
- Evaluation of secondhand smoke effects on CFTR function in vivo.Respiratory research · 2020Article
- Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatients heterozygous for mutations in the
methodsWe conducted a retrospective case-control study using health insurance claims. We identified patients as either highly likely to be
results
conclusionsPatients heterozygous for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.